Siponimod in the treatment of multiple sclerosis

References

• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Sospedra M, Martin R. Immunology of multiple sclerosis. Semin Neurol. 2016 Apr;36(2):115–127.
   PubMed Web of Science ®Google Scholar
• Owens GP, Bennett JL, Gilden DH, et al. The B cell response in multiple sclerosis. Neurol Res. 2006 Apr;28(3):236–244.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):221–234.
   PubMed Web of Science ®Google Scholar
• Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012 Nov 5;8(11):647–656.
   PubMed Web of Science ®Google Scholar
• Mandolesi G, Gentile A, Musella A, et al. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat Rev Neurol. 2015 Dec;11(12):711–724.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):209–220.
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013 May;31(5):CD002127.
   Google Scholar
• Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004 Sep 25–Oct 1;364(9440):1149–1156.
   PubMed Web of Science ®Google Scholar
• La Mantia L, Vacchi L, Di Pietrantonj C, et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev. 2012 Jan;18(1):CD005181.
   Google Scholar
• Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 May;17(5):405–415.
   PubMed Web of Science ®Google Scholar
• Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003 Jan 14;60(1):44–51.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct;66(4):460–471.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007 Jan;61(1):14–24.
   PubMed Web of Science ®Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075–1084.
   PubMed Web of Science ®Google Scholar
• Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000 Mar 14;54(5):1145–1155.
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995 Jan;37(1):30–40.
   PubMed Web of Science ®Google Scholar
• Wiendl H, Kieseier BC, Weissert R, et al. Treatment of active secondary progressive multiple sclerosis with treosulfan. J Neurol. 2007 Jul;254(7):884–889.
   PubMed Web of Science ®Google Scholar
• Siponimod. version 5.1.1; 2018 Jul 3 [cited 2018 Jul 14]. Available from: https://www.drugbank.ca/drugs/DB12371
   Google Scholar
• Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs. 2015 Jul;29(7):565–575.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002 Apr 12;296(5566):346–349.
   PubMed Web of Science ®Google Scholar
• Camm J, Hla T, Bakshi R, et al. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J. 2014 Nov;168(5):632–644.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453–21457.
   PubMed Web of Science ®Google Scholar
• Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012 Nov;167(5):1035–1047.
   PubMed Web of Science ®Google Scholar
• Legangneux E, Gardin A, Johns D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol. 2013 Mar;75(3):831–841.
   PubMed Web of Science ®Google Scholar
• Jaillard C, Harrison S, Stankoff B, et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci. 2005 Feb 9;25(6):1459–1469.
   PubMed Web of Science ®Google Scholar
• Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017 Oct;14(4):859–873.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Comi G, Arnold DL, et al. Efficacy and safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study. Mult Scler. 2018;25:1352458518789884.
   Web of Science ®Google Scholar
• Brossard P, Derendorf H, Xu J, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76(6):888–896.
   PubMed Web of Science ®Google Scholar
• Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (OPTIMUM). 2018 Dec 20 [cited 2019 Jan 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02425644
   Google Scholar
• Glaenzel U, Jin Y, Nufer R, et al. Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001–1013.
   PubMed Web of Science ®Google Scholar
• Jin Y, Borell H, Gardin A, et al. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. Eur J Clin Pharmacol. 2018 Apr;74(4):455–464.
   PubMed Web of Science ®Google Scholar
• Gardin A, Ufer M, Legangneux E, et al. Effect of fluconazole coadministration and CYP2C9 genetic polymorphism on siponimod pharmacokinetics in healthy subjects. Clin Pharmacokinet. 2019 Mar;58(3):349–361.
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007 Aug 1;76(3):391–396.
   PubMed Web of Science ®Google Scholar
• Shakeri-Nejad K, Aslanis V, Veldandi UK, et al. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study. Int J Clin Pharmacol Ther. 2017 Jan;55(1):41–53.
   PubMed Web of Science ®Google Scholar
• Gardin A, Dodman A, Kalluri S, et al. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: a single-dose, open-label, parallel-group study. Int J Clin Pharmacol Ther. 2017 Jan;55(1):54–65.
   PubMed Web of Science ®Google Scholar
• Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013 May 15;328(1–2):9–18.
   PubMed Web of Science ®Google Scholar
• Tavares A, Barret O, Alagille D, et al. Brain distribution of MS565, an imaging analogue of siponimod (BAF312), in non-human primates (P1.168). Neurology. 2014;82(10 Supplement).
   Google Scholar
• Gentile A, Musella A, Bullitta S, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016 Aug 26;13(1):207.
   PubMedGoogle Scholar
• O’Sullivan C, Schubart A, Mir AK, et al. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016 Feb 8;13:31.
   PubMed Web of Science ®Google Scholar
• Lin W, Lin Y, Li J, et al. Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis. J Neurosci. 2013 Apr 3;33(14):5980–5991.
   PubMed Web of Science ®Google Scholar
• Tiwari-Woodruff S, Yamate-Morgan H, Sekyi M, et al. The sphingosine 1-phosphate (S1P) receptor modulator, siponimod decreases oligodendrocyte cell death and axon demyelination in a mouse model of multiple sclerosis. Neurology. 2016 Apr;86(16supplement).
   Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004 Jan 22;427(6972):355–360.
   PubMed Web of Science ®Google Scholar
• Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008 Oct 14;71(16):1261–1267.
   PubMed Web of Science ®Google Scholar
• Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013 Aug;12(8):756–767.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402–415.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li DK, Stuve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016 Sep 1;73(9):1089–1098.
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263–1273.
   PubMed Web of Science ®Google Scholar
• Panitch H, Miller A, Paty D, et al. North American Study Group on interferon beta-1b in secondary progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004 Nov 23;63(10):1788–1795.
   PubMed Web of Science ®Google Scholar